Ipsen : New investigational clinical data for Ipsen's oncology products in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting -Today at 11:53 am

Paris , 24 May 2019 - Ipsen today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib , liposomal irinotecan , and lanreotide autogel will...

Related Keywords

United States ,France ,Chicago ,Illinois ,American ,Alexandre Lebeaut ,Cabozantinib Nivolumab ,Ipilimumab Cabonivoipi ,Ipsen Euronext ,European Organization For Research ,Renal Cell Cancer Alliance ,American Society Of Clinical Oncology ,Somatuline Depot ,Clinical Oncology ,European Organization ,Executive Vice President ,Chief Scientific ,Neck Cancer ,Irinotecan Liposome Injection ,Small Cell Lung Cancer ,Preliminary Findings ,Lung Cancer Non Small Cell ,Lanreotide Autogel ,Results From ,Renal Cell Cancer ,Skin Cancers ,Markets ,